Recurrence Dynamics for Non–Small-Cell Lung Cancer: Effect of Surgery on the Development of Metastases  by Demicheli, Romano et al.
723Journal of Thoracic Oncology  •  Volume 7, Number 4, April 2012
oRIGINAL ARTICLE
Introduction: We study event rates over time (event dynamics) in 
patients undergoing surgery for early-stage non–small-cell lung can-
cer (NSCLC).
Methods: Using a database of patients undergoing initial surgery for 
NSCLC, the event dynamics, based on the hazard rate, were evalu-
ated. Events evaluated included time to any treatment failure, local 
recurrence, distant metastasis (DM), and development of a second 
primary lung cancer.
Results: Among 1506 patients, time to any treatment failure dynam-
ics demonstrated an initial surge in the hazard rate 9 months after 
surgery, followed by two smaller peaks at the end of the second and 
fourth years, respectively. This pattern was dominated by DM events. 
Two distinguishable peaks were noted for local recurrence in the first 
and second years. In contrast, the hazard rate for second primary lung 
cancer exhibited a more uniform pattern over time. The DM dynam-
ics was analyzed by sex and three peaks emerged for both sexes. The 
timing of the first peak was similar for both sexes, at 7 to 9 months 
after surgery. The second peak occurred earlier in men (18–20 
months) than women (24–26 months). For both sexes the third peak 
appeared during the fourth year.
Conclusions: Recurrence dynamics of resected early-stage NSCLC 
displays a multipeak pattern, which supports the hypothesis of a 
metastasis growth model previously described for early-stage breast 
cancer. The model assumes both cellular and micrometastatic tumor 
dormancy and a transient phase of acceleration of metastatic growth 
following surgical excision of the primary tumor.
Key Words: NSCLC, Recurrence dynamics, Tumor dormancy, 
Surgery effect, Tumor homeostasis.
(J Thorac Oncol. 2012;7: 723–730)
Lung cancer is the leading cause of cancer death in the United States and Europe,1,2 and non–small-cell lung can-
cer (NSCLC) comprises approximately 85% of the cases. 
Surgery is the preferred initial treatment for patients with 
stage I to II (N0–N1) disease. Unfortunately, despite having 
early disease, a significant proportion (30–60%) will develop 
a local and/or distant recurrence.3 Although adjuvant plat-
inum-based chemotherapy improves survival, the benefits 
are modest.4 Several current studies are evaluating a com-
bination of chemotherapy and molecules blocking specific 
molecular targets.5
The time between surgery and the development of a 
recurrence may provide insights into the kinetics of micro-
scopic tumor deposits. There are alternative statistical meth-
ods to describe risks of recurrence in relation to time after a 
definitive course of therapy for a population of patients. Most 
frequently, cumulative incidence curves are used, i.e., the 
cumulative risk of incurring an event (e.g., local failure and 
distant failure) over time. They do not provide direct informa-
tion about changes of event probabilities over time, e.g., the 
event dynamics, which can be estimated by the event-specific 
hazard rate over follow-up time interval.6
Event dynamics have been extensively studied in patients 
with breast cancer. Following surgery, the rate of both local and 
distant recurrence oscillates on a regular basis over time. This 
suggests that microscopic tumor cell deposits may not grow 
at a consistent rate, and raises the possibility that there are 
interactions among the growth rate of microscopic tumor cell 
deposits, the resection of the primary tumor, and other host-
specific physiological factors. These findings have been seen 
in patients with early breast cancer undergoing primary tumor 
removal with or without adjuvant chemotherapy7,8 and have 
been extensively validated in 12 independent databases.9–21 
The recurrence dynamics in early breast cancer proved to be 
stable for all analyzed subsets (by tumor size, nodal status, 
oestrogen receptor content, and menopausal status) of patients 
undergoing both radical and conservative surgery,22–24 and for 
all sites of metastases.25
on the basis of these observations, we and others created 
a new model of metastasis development based on the concepts 
of tumor homeostasis, tumor dormancy, and surgery-related 
enhancement of metastasis growth.26 The model, which is 
consistent with the available event dynamics data, assumes 
cellular and micrometastatic tumor dormancy, with ordered 
transitions between these two quiescent states and subsequent 
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development of overt metastasis and, in addition, a transient 
phase of acceleration of metastatic growth following surgical 
excision of the primary tumor.26,27
We herein reassess this issue in a series of patients under-
going surgery for NSCLC. The event dynamics of lung cancer 
patients are also compared to that seen in patients undergoing 
surgery for breast cancer. Finally, because the breast cancer 
data were derived from women, and the lung data from both 
women and men, we also assess sex-specific event dynamics 
after surgery.
MATERIALS AND METHODS
This Institutional Review Board-approved retrospective 
analysis included all patients who underwent initial surgery 
for T1 to T3a, N0 to N2 NSCLC (TNM 7) between 1995 and 
2008 at Duke University Medical Center.28 All patients were 
diagnosed with a single primary tumor, did not receive pre-
operative chemotherapy and/or radiation therapy, and did not 
have a prior history of lung cancer. Patients who died in the 
immediate postoperative period (within 30 days of surgery or 
during the initial hospitalization) were excluded. All patients 
had routine postsurgical surveillance with imaging studies, 
including chest computed tomography, but frequency and 
choice of follow-up imaging modality were not standardized.
Patterns of failure were assessed by follow-up imaging 
studies and more invasive procedures including bronchoscopy, 
mediastinoscopy, and computed tomography-guided biopsies. 
Disease recurrence at the surgical resection margin, ipsilateral 
hilum, and/or mediastinum was considered a local recurrence 
(LR). All other sites of failure, including the supraclavicular 
fossa and contralateral hilum, were considered sites of dis-
tant metastases (DM). A second primary (SP) lung cancer was 
scored when a patient presented with a different histology or 
the same histology but a clinical presentation that was most 
consistent with a new primary tumor (e.g., single pulmonary 
parenchymal lesion in a different pulmonary lobe than the 
index lesion, without evidence of disease elsewhere). All fail-
ures, including SP lung malignancies, were reviewed by two 
clinicians to ensure accuracy.
To study analogies between recurrence dynamics of 
NSCLC and breast cancer, data of premenopausal patients 
with axillary lymph node invasion given mastectomy only, 
without any other adjuvant treatment, were extracted from the 
database used for the investigation reported in Ref. 7 and were 
analyzed with the same modality as NSCLC patients.
Time to treatment failure was defined as the interval 
between the date of surgery to date of disease recurrence (LR 
or DM) or development of an SP. only first events were con-
sidered. The event dynamics were studied by estimating with 
the life-table method the discrete hazard rate for the consid-
ered event, i.e., the conditional probability of manifesting the 
event in a time interval, given that the patient did not previ-
ously experience it at the beginning of the interval. A discreti-
zation of the time axis in 2-month units was applied, and all 
hazard rate levels were measured as “events/patients at risk 
per 2-month interval.” Because the hazard rate estimates dis-
play some instability owing to random variation, a Kernel-like 
smoothing procedure29 was adopted and the smoothed curve 
was graphically represented to make it easier for the reader to 
see the underlying pattern. In addition to the Kernel smooth-
ing approach with discrete hazards, a flexible piecewise 
exponential regression model was also performed to obtain 
smoothed hazard estimates.30 Natural cubic splines, i.e., with 
linearity constraints on the tails, were used with internal knots 
placed equidistantly within the month range (0–60 months), 
with the exception of the comparison between lung and breast 
cancer, where the interval of observation was prolonged to 72 
months. The number of knots, corresponding to a number of 
basis functions between 4 and 10, was chosen according to the 
Akaike Information Criterion (AIC). The 95% pointwise con-
fidence intervals were based on the log transformation. For a 
comparison with a penalized regression approach, P-splines31 
were also used. These established smoothing approaches were 
used in previous reports.7,8,21–27
RESULTS
A total of 1559 patients fitting the study conditions 
were identified. As 53 of them suffered postoperative mor-
tality and were not evaluated further, this analysis included 
1506 patients. Patient, tumor, and treatment characteris-
tics can be found in Table 1. At a median follow-up of 60 
months (range, 1–177 months) 389 patients developed dis-
ease recurrence (103 LR only, 86 LR and DM, and 200 DM 
only). SP lung malignancy was documented in an additional 
73 patients.
Comparison of Recurrence Dynamics Following 
Surgery for Lung Cancer
We first analyzed the hazard rate for treatment failure 
for all 1506 patients. The resulting curve (Fig. 1) displays an 
initial surge in the hazard rate that peaks at about 9 months 
following surgery. A further distinct peak is noted at the end 
of the second year of follow-up and a third smaller increase of 
the hazard rate during the fourth year.
Dividing disease recurrence into different events by 
location (LR versus DM) raised the problem of classifying 
events where DM and LR occurred at the same time (about 
30% of DM). We therefore considered three kinds of events, 
i.e., LR alone, DM alone, and LR 1 DM, which were sepa-
rately analyzed. The DM alone and LR 1 DM (Supplemental 
Fig. S1, Supplemental Digital Content 1, http://links.lww.
com/JTo/A234) events show similar multipeak patterns 
with the Kernel-like smoothing procedure, whereas the 
apparent inconsistency of the piecewise exponential regres-
sion is due to the choice of a conservative model through 
AIC selection owing to the relatively low number of DM 
with contemporary LR. Actually, by using more knots than 
suggested by AIC, a pattern analogous to the Kernel-like 
one is gained. When considering the consistent dynamic 
pattern for the DM alone and LR 1 DM combined with the 
concept of clinical dominance of the worse event, we com-
bined these groups as DM.
Using this classification, DM, LR, and SP were sepa-
rately considered and the three event dynamics were ana-
lyzed (Fig. 2). Three peaks are clearly detectable in the DM 
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hazard rate curve. In the LR hazard curve, although the two 
early peaks are well identifiable, there are inflections seem-
ingly matching peaks of the hazard curve for DM, in keeping 
with the reported classification criteria. In contrast, the hazard 
rate for SP exhibits a unique pattern. After a smooth increase 
during the first 18 to 24 months, the hazard rate is relatively 
constant thereafter, suggesting that SP tumors have a distinct 
biology compared with recurrent tumors. Moreover, such a 
pattern provides indirect support to the fact that the authors 
were able to reliably differentiate between SP and LR.
As development of brain metastases after surgery 
was carefully recorded in the database, we compared the 
nonbrain DM dynamics with the brain metastases dynam-
ics (Supplemental Fig. S2, Supplemental Digital Content 2, 
http://links.lww.com/JTo/A235). The shapes of the two haz-
ard curves are remarkably similar, despite the fact that the 
actuarial risk of developing brain metastases is much lower 
than the corresponding risk for nonbrain metastases. of note, 
the similarity was maintained also when the hazard rate for 
DM without concomitant LR was analyzed for both brain and 
nonbrain metastases (Supplemental Fig. S3, Supplemental 
Digital Content 3, http://links.lww.com/JTo/A236).
The DM dynamics was then analyzed by sex; three 
peaks emerged for both sexes, although with a few different 
timing traits (Fig. 3). The timing of the first peak is similar 
for both sexes, at 7 to 9 months after surgery, whereas the 
second peak occurs earlier in men (at about 18–20 months) 
than women (at about 24–26 months). For both men and 
women the third peak arises during the fourth year, when the 
number of events is inadequate to assess more subtle timing 
differences.
Comparison of Recurrence Dynamics Following 
Surgery for Breast Cancer versus Lung Cancer
The DM dynamics data from the women with lung 
cancer were compared to the DM dynamics in 251 premeno-
pausal patients with breast cancer who were treated with sur-
gery alone. All patients of this old series had axillary lymph 
node involvement and were managed with mastectomy with-
out any adjuvant treatment. The hazard rate curves (Fig. 4, 
where the time axis is prolonged to 72 months to include the 
third peak of breast cancer patients) display similar patterns 
with three peaks, though the timings of the peaks do not coin-
cide. Peaks for breast cancer occur with a delay of about 3, 6, 
and 24 months in comparison with the corresponding peaks 
for NSCLC.
TABLE 1. Patient, Treatment, and Tumor Characteristics  
(n 5 1506)
Characteristic %
Age (yr)
 Median 68
 Range 21–93
Sex (no.)
 Male 795 52.8
 Female 711 47.2
Race (no.) 
 White 1274 84.6
 Black 200 13.3
 other 32 2.1
Stage (no.)
 IA 618 41
 IB 401 26.7
 IIA 257 17.1
 IIB 122 8.1
 IIIA 108 7.1
Tumor size (cm)
 Mean 3.3
 Median 2.7
 Range 0.3–14
Location (no.)
 Right upper lobe 550 36.5
 Right middle lobe 73 4.9
 Right lower lobe 231 15.3
 Right lung, NoS 12 0.8
 Left upper lobe 419 27.8
 Left lower lobe 215 14.3
 Left lung, NoS 6 0.4
Surgical approach (no.)
 open 753 50
 VATS 753 50
Surgical procedure (no.)
 Wedge 237 15.7
 Segmentectomy 60 4.0
 Lobectomy 996 66.1
 Sleeve resection 63 4.1
 Bilobectomy 58 3.9
 Pneumonectomy 92 6.1
Surgical margins (no.)
 Negative 1453 96.5
 Positive 53 3.5
Lymphovascular space invasion (no.)
 Yes 342 22.7
 No 1065 70.7
 NS 99 6.6
Visceral pleural invasion (no.)
 Yes 357 23.7
 No 1085 72.0
 NS 64 4.3
Histology (no.)
 Adenocarcinoma 741a 49.2
 Squamous cell 530 35.2
 Large cell 90 6
 Bronchioloalveolar 39 2.6
 NSCLC, NoS 106 7
Adjuvant chemotherapy (no.) 185 12.3
Adjuvant radiotherapy (no.) 62 4.1
aIncluding adenosquamous (n 5 20).
VATS, video-assisted thoracoscopic surgery; NoS, not otherwise specified; NSCLC, 
non–small-cell lung cancer; NS, not stated.
TABLE 1. (Continued )
Characteristic %
(Continued)
726 Copyright © 2012 by the International Association for the Study of Lung Cancer
Demicheli et al. Journal of Thoracic Oncology  •  Volume  7, Number 4, April 2012
DISCUSSION
The primary finding of this investigation is the discovery 
that the recurrence dynamics of resected early-stage NSCLC 
displays a structured pattern with clustering of recurrences at 
given times after surgery. This contrasts with the pattern of 
SP lung cancers, where the hazard rate is essentially constant 
during the follow-up interval.
In the past, the rapid dramatic course of lung cancer has 
often been considered a consequence of relentless growth. The 
finding that DM dynamics displays a structured pattern sheds 
major doubts upon this picture. Indeed, peaks in the hazard 
rate were observed clustering around different time points, 
implying fluctuating rates of tumor growth, a novel finding for 
NSCLC. Also, it could be argued that tumor growth rates vary 
by anatomical metastatic sites. However, this is contradicted 
by the finding that brain metastases and nonbrain metastases 
display the same dynamics (Fig. 4), thus reasonably exclud-
ing site-specific growth patterns. Therefore, our findings do 
not seem compatible with continuous tumor growth. Rather, 
our findings suggest that some kind of growth interruption, 
i.e., tumor dormancy, is very likely. Moreover, the sharp peak 
shortly after surgery suggests a possible role of primary tumor 
surgical removal on the disease course: the idea that surgi-
cal cancer resection has both beneficial and adverse effects 
on cancer spread and growth that result from the modulation 
of tumor dormancy by the resection has roots in both experi-
mental and clinical literatures that stretch back more than a 
century32–39 (reviewed in Ref. 27).
A further interesting result is that peak timing proved to 
be somehow sex dependent (Fig. 3), whereas other analyzed 
factors (histology, stage, age, and race) were not contribu-
tory (data not shown). No meaningful sex-related difference 
is detectable for the first peak, suggesting that in both sexes 
the corresponding rate of developing metastases is similar. In 
contrast, there is a 6-month difference between the timing of 
the second peak in women and men, suggesting that the cor-
responding metastasis development is delayed in women in 
FIGURE 1. Cause-specific hazard rate estimates for first 
event (local recurrence [LR] plus distant metastasis [DM] 
plus second primary [SP]) in 1506 patients undergoing 
surgery with curative intent for early-stage non–small-cell 
lung cancer. Time origin at surgery. A, Hazard rate within a 
2-month interval. Smoothed curves are obtained by a Kernel-
like smoothing procedure. Standard deviation estimates for 
single points are also reported. B, Hazard rate obtained by 
the piecewise exponential regression approach described in 
the Methods section. Vertical lines represent 95% pointwise 
confidence intervals.
FIGURE 2. Cause-specific hazard rate estimates for local 
recurrence, distant metastasis, and second primary in 1506 
patients undergoing surgery with curative intent for early-
stage non–small-cell lung cancer. Time origin at surgery. A, 
Hazard rate within a 2-month interval. Smoothed curves are 
obtained by a Kernel-like smoothing procedure. B, Hazard 
rate obtained by the piecewise exponential regression 
approach described in the Methods section. Vertical lines 
represent 95% pointwise confidence intervals.
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comparison with men. No definite conclusion can, at present, 
be drawn about the third peak because of the limited num-
ber of events in the corresponding time span, so the question 
of sex-dependent similarity or difference in late peak timing 
remains unresolved, needing more patients and longer surveil-
lance time. For this reason, only a discussion on the two earlier 
peaks is considered meaningful.
How can these findings be explained? A structured mul-
tipeak pattern of recurrence risk is not a new finding in oncol-
ogy, as it was revealed in the past for breast cancer26 and for 
head and neck cancer.40 In particular, the NSCLC recurrence 
dynamics for women exhibits impressive analogies with the 
corresponding dynamics for early breast cancer (Fig. 4). Hence, 
it may be convenient to try to understand the NSCLC clinical 
behavior by assuming a tumor biology similar to that of breast 
cancer.26,41 According to this biology (Fig. 5), the develop-
ment of metastases includes sequential passage through a few 
phases following tumor cell shedding from the primary: (1) 
single, mostly nondividing, tumor cells (cellular dormancy), 
(2) nonangiogenic micrometastases (and angiogenic ones in the 
presence of antiangiogenic factors) that cannot grow more than 
the size of avascular foci (micrometastatic dormancy), and (3) 
vascularized growing metastases destined to reach the clinical 
level. This orderly process may be controlled by the primary 
tumor that can exert restraints on the transition between dor-
mancy phases, thus retarding or inhibiting metastasis devel-
opment. Therefore, surgical removal of primary tumor may 
disrupt tumor homeostasis, with sudden acceleration of the 
metastatic process, at least for some patients.
The model reasonably explains the findings of this 
study. The early sharp peak of the recurrence risk for both 
men and women can be ascribed to the surgery-related switch-
ing of micrometastatic foci to the angiogenic phenotype. In 
other words, when the primary tumor (which may be secreting 
antiangiogenic factors, as occurs in a few animal models)42 is 
removed, the biological balance favors an angiogenic environ-
ment, with a rapid activation and growth of some small micro-
metastases that become clinically apparent. The steep increase 
of the first peak may be considered a sign of this triggering 
effect and the remarkable coincidence of the peak position for 
both sexes suggests similar growth rate in men and women. 
The second peak may result from a two-step process. In the 
first step, the surgery-induced proliferation of single cells 
results in sudden temporary growth toward micrometastatic 
dormancy when tumor growth discontinues. The next step is 
dependent on the ability of the micrometastases to switch to 
the angiogenic phenotype, which is tumor and host related.43 
It not surprising, therefore, that switching to the angiogenic 
phenotype may be sex related. Indeed, there are sex-related 
dissimilarities between men and women, which are relevant 
to angiogenesis. For example, a sex-related trait is the waxing 
and waning of levels of angiogenesis inducers and inhibitors 
during the menstrual cycle in women. Differences are not con-
fined to premenopause.44 Consequently, the sex-related inner 
milieu of the host may have selected tumor cells with different 
traits and/or may differently act on them in men and women, 
thus resulting in different sojourn times in the micrometastatic 
FIGURE 3. Cause-specific hazard rate estimates for distant metastasis in 795 men (right) and 711 women (left) undergoing 
surgery with curative intent for early-stage non–small-cell lung cancer. Time origin at surgery. A, Hazard rate within a 2-month 
interval. Smoothed curves are obtained by a Kernel-like smoothing procedure. Standard deviation estimates for single points 
are also reported. B, Hazard rate obtained by the piecewise exponential regression approach described in the Methods section. 
Vertical lines represent 95% pointwise confidence intervals.
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dormancy phase, accounting for the different timing of the 
second peak.
A few features from the comparison between breast can-
cer and NSCLC in women (Fig. 4) are worth mentioning. Breast 
cancer patients display a slightly delayed first peak compared 
with NSCLC patients, which is well compatible with the fact 
that breast cancer has a slower growth rate than NSCLC. The 
difference in the second peak timing between the two tumor 
types (about 6 months) may result from both slower growth 
rate and longer sojourn time in the avascular dormancy phase. 
A definitely longer delay occurs for the third peak, although 
its exact position for NSCLC patients is still uncertain, that 
may be ascribed to a further difference in the sojourn time 
in the cellular dormancy phase. Therefore, shorter dormancy 
times and faster growth rate may explain different timing val-
ues yet similar pattern for NSCLC in comparison with breast 
cancer so that the hazard curve of the former tumor looks like 
a compressed copy of the hazard curve of the latter. of note, 
just like NSCLC, brain metastases recurrences for breast can-
cer display the same dynamics as other metastases.25
Let us address a few objections to the authenticity of the 
findings of this investigation. Peaks could be considered as an 
artifact because of random variation. Yet, the coherent profile of 
the hazard curve for DM and LR in contrast with the very differ-
ent constant hazard rate for SP tumors (Fig. 2) and the remarkable 
similarity between the patterns of hazard rate for brain metastasis 
and nonbrain metastasis (Supplemental Fig. S2, Supplemental 
Digital Content 2, http://links.lww.com/JTo/A235) oppose this 
view. Moreover, the estimate of the hazard rate by spline func-
tions according to AIC takes care of overfitting by the balance 
between model bias and variance. others could ascribe the haz-
ard patterns as an artifact caused by follow-up intervals when 
surveillance imaging studies are routinely obtained. It should be 
noted, however, that (1) follow-up intervals were not standard-
ized; (2) a high percentage of NSCLC recurrences is detected 
because of symptom appearance, regardless of the scheduled 
follow-up45; (3) despite the same follow-up imaging modalities, 
peaks occur at different times for men and women and second 
lung primaries do not display any peak. Hence, although the 
occurrence of an artifact is a possibility, it seems unlikely.
FIGURE 5. Outline of the metastatic process. Tumor cells 
leave the primary as single cells and seed the distant tissue 
where they may lodge for some time in a quiescent state or 
go on proliferating. Quiescent cells can be induced to pro-
liferate by intrinsic or microenvironmental changes and will 
grow toward nonangiogenic micrometastases (and angio-
genic ones in the presence of antiangiogenic factors) that 
cannot grow more than the size of avascular foci. The further 
growth phase implies the absence or the removal of angio-
genesis inhibitors to release those already capable of inducing 
neovascularization, or the switch to an angiogenic phenotype 
of a subset of tumor cells within not-yet angiogenic microme-
tastases. After the beginning of the vascular phase micro-
metastases may grow until overt clinical recurrence. There is 
evidence that the presence of the primary tumor may exert 
some kind of homeostatic effect upon distant metastases, 
resulting in inhibited proliferation and/or enhanced apop-
tosis. In the presurgical condition the primary tumor may 
restrain transitions, thus concurring to, if not determining, 
the cellular and micrometastatic dormancy. Primary tumor 
removal, consequently, will enhance transitions and fuel the 
metastatic process. 
FIGURE 4. Cause-specific hazard rate estimates for distant 
metastasis in 711 women undergoing surgery with curative 
intent for early-stage non–small-cell lung cancer and in 251 
premenopausal patients with axillary lymph node invasion 
who were treated with mastectomy alone for early-stage 
breast cancer. Time origin at surgery. A, Hazard rate within 
a 2-month interval. Smoothed curves are obtained by a 
Kernel-like smoothing procedure. B, Hazard rate obtained by 
the piecewise exponential regression approach described in 
the Methods section. Vertical lines represent 95% pointwise 
confidence intervals.
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In conclusion, our analysis shows for the first time that 
the recurrence dynamics of resected early-stage NSCLC dis-
plays a multipeak pattern, with striking similarities with the 
corresponding dynamics observed in early breast cancer. The 
same metastasis development model explaining a postopera-
tive breast cancer course, which assumes both cellular and 
micrometastatic tumor dormancy, with ordered transitions 
between these two quiescent states and subsequent develop-
ment of overt metastasis and, in addition, a transient phase of 
acceleration of metastatic growth following surgical excision 
of the primary tumor, apparently explains the clinical data for 
NSCLC as well. The NSCLC biology of the subclinical phase 
opens new perspectives for more targeted adjuvant treatments. 
For example, it suggests that there are a few windows of active 
tumor cell proliferation, when metastases are more sensitive 
to cytotoxic drugs and/or angiogenesis inhibitors. By contrast, 
other phases may be quite refractory to standard treatments.
our analysis supports the hypothesis of both cellular 
and micrometastatic dormancy phases as fundamental features 
of tumor development. From a more general point of view, 
it is conceivable that similar recurrence dynamics, although 
with specific tumor-related traits, are present for other neo-
plasias as well. Investigations on this issue are warranted and 
ongoing. Examining the mechanisms underlying dormancy 
maintenance and interruption emerges as a crucial goal for 
understanding and effectively treating malignancies.
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